[Federal Register Volume 81, Number 248 (Tuesday, December 27, 2016)]
[Notices]
[Pages 95143-95145]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-31145]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2016-D-1495]
Factors to Consider Regarding Benefit-Risk in Medical Device
Product Availability, Compliance, and Enforcement Decisions; Guidance
for Industry and Food and Drug Administration Staff; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of availability.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the availability of the guidance entitled ``Factors to Consider
Regarding Benefit-Risk in Medical Device Product Availability,
Compliance, and Enforcement Decisions.'' This guidance is intended to
provide clarity for FDA staff and industry regarding the benefit and
risk factors FDA may consider in prioritizing resources for compliance
and enforcement efforts to maximize medical device quality and patient
safety. Although product availability and other medical device
compliance and enforcement decisions are generally fact-specific, FDA
believes that explaining how we consider the factors listed in the
guidance will improve the consistency and transparency of these kinds
of decisions. A common understanding of how FDA considers benefit and
risk may better align industry's and FDA's focus on actions that
maximize benefit to patients, improve medical device quality, and
reduce risk to patients. This guidance is in effect at this time.
DATES: Submit either electronic or written comments on this guidance at
any time. General comments on Agency guidance documents are welcome at
any time.
ADDRESSES: You may submit comments as follows:
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
[[Page 95144]]
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Division of
Dockets Management, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2016-D-1495 for the guidance entitled ``Factors to Consider
Regarding Benefit-Risk in Medical Device Product Availability,
Compliance, and Enforcement Decisions.'' Received comments will be
placed in the docket and, except for those submitted as ``Confidential
Submissions,'' publicly viewable at https://www.regulations.gov or at
the Division of Dockets Management between 9 a.m. and 4 p.m., Monday
through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Division of Dockets Management. If you do not
wish your name and contact information to be made publicly available,
you can provide this information on the cover sheet and not in the body
of your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: http://www.fda.gov/regulatoryinformation/dockets/default.htm.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Division of Dockets Management, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
An electronic copy of the guidance document is available for
download from the Internet. See the SUPPLEMENTARY INFORMATION section
for information on electronic access to the guidance. Submit written
requests for a single hard copy of the guidance document entitled
``Factors to Consider Regarding Benefit-Risk in Medical Device Product
Availability, Compliance, and Enforcement Decisions'' to the Office of
the Center Director, Guidance and Policy Development, Center for
Devices and Radiological Health, Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 66, Rm. 5431, Silver Spring, MD 20993-0002.
Send one self-addressed adhesive label to assist that office in
processing your request.
FOR FURTHER INFORMATION CONTACT: Ann M. Ferriter, Center for Devices
and Radiological Health, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, Rm. 3680, Silver Spring, MD 20993, 301-796-
5530.
SUPPLEMENTARY INFORMATION:
I. Background
The guidance is intended to provide a framework for FDA and
stakeholders that sets forth overarching benefit-risk principles. FDA
may consider the types of benefit-risk factors described in the
guidance--including reliable patient input from a representative
sample--on a case-by-case basis when determining the appropriate
regulatory actions to take and to help ensure that informed and
science-based decisions are made to the greatest extent practicable.
Factors may be weighted differently for different decisions and as the
timeframe allows. FDA intends to use pilots and other evaluation
techniques to help determine how to apply the benefit-risk framework
described in this guidance. Because of the variability in the facts of,
and data available for, each decision, specific factors that will
inform FDA's thinking may vary.
In addition, the guidance is intended to harmonize FDA's approach
to weighing benefits and risks for medical device product availability,
compliance, and enforcement decisions with FDA's benefit-risk framework
for evaluating medical device marketing and investigational device
exemption applications. The benefit-risk factors in the guidance also
support assessment of medical devices with real world evidence.
The framework described in the guidance may be applicable to
industry and FDA decisions. The benefit-risk factors may be considered
when device manufacturers evaluate appropriate responses to
nonconforming product or regulatory compliance issues, such as
determining whether to limit the availability of a medical device
(e.g., a voluntary recall or market withdrawal). FDA may consider the
benefit-risk factors during, for example, the evaluation of device
shortage situations, selection of the appropriate regulatory engagement
mechanism following an inspection during which regulatory non-
compliance was observed, evaluation of recalls and consideration of
petitions for variance from those sections of the Quality System
regulation (21 CFR part 820) for which there were inspectional
observations during a premarket approval preapproval inspection.
The guidance applies to both diagnostic and therapeutic medical
devices subject to, and exempt from, premarket review. The scope of the
guidance excludes medical devices regulated by FDA's Center for
Biologics Evaluation and Research combination products, as defined in
21 CFR 3.2(e), for which the Center for Devices and Radiological Health
(CDRH) is not the lead Center; and electronic products that are not
devices as defined in section 201(h) of the Federal Food, Drug, and
Cosmetic Act (the FD&C Act) (21 U.S.C. 321(h)) as regulated by CDRH
under the Electronic Product Radiation Control provisions in the FD&C
Act and implementing regulations (21 CFR Subchapter J--Radiological
Health). This guidance does not apply to products (e.g., drugs,
biologics, dietary supplements, foods, tobacco products, or cosmetics)
regulated by other FDA Centers.
In the Federal Register of June 16, 2016 (81 FR 39272), FDA
published a notice of availability for the draft guidance entitled
``Factors to Consider Regarding Benefit-Risk in Medical Device Product
Availability, Compliance, and Enforcement Decisions.'' FDA considered
the comments received on the draft guidance and has revised the
guidance as appropriate in response to the comments.
II. Significant of Guidance
This guidance is being issued consistent with FDA's good guidance
[[Page 95145]]
practices regulation (21 CFR 10.115). The guidance represents the
current thinking of FDA on ``Factors to Consider Regarding Benefit-Risk
in Medical Device Product Availability, Compliance, and Enforcement
Decisions.'' It does not establish any rights for any person and is not
binding on FDA or the public. You can use an alternative approach if it
satisfies the requirements of the applicable statutes and regulations.
III. Electronic Access
Persons interested in obtaining a copy of the guidance may do so by
using the Internet. A search capability for all CDRH guidance documents
is available at http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm. Guidance
documents are also available at https://www.regulations.gov. Persons
unable to download an electronic copy of ``Factors to Consider
Regarding Benefit-Risk in Medical Device Product Availability,
Compliance, and Enforcement Decisions'' may send an email request to
[email protected] to receive an electronic copy of the
document. Please use the document number 1500065 to identify the
guidance you are requesting.
IV. Paperwork Reduction Act of 1995
This guidance refers to previously approved collections of
information found in FDA regulations. These collections of information
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The
collections of information in 21 CFR part 7, subpart C, have been
approved under OMB control number 0910-0249. The collections of
information in 21 CFR parts 801 and 809, regarding labeling, have been
approved under OMB control number 0910-0485. The collections of
information in 21 CFR part 803, regarding medical device reporting,
have been approved under OMB control numbers 0910-0291, 0910-0437, and
0910-0471. The collections of information in 21 CFR part 806 have been
approved under OMB control number 0910-0359. The collections of
information in 21 CFR part 807, subpart E, have been approved under OMB
control number 0910-0120. The collections of information in 21 CFR part
810, regarding medical device recall authority, have been approved
under OMB control number 0910-0432. The collections of information in
21 CFR part 812 have been approved under OMB control number 0910-0078.
The collections of information in 21 CFR part 814, subparts B and E,
have been approved under OMB control number 0910-0231. The collections
of information in 21 CFR part 820, regarding the Quality System
regulation, have been approved under OMB control number 0910-0073. The
collections of information in 21 CFR part 822, regarding postmarket
surveillance of medical devices, have been approved under OMB control
number 0910-0449.
Dated: December 21, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-31145 Filed 12-23-16; 8:45 am]
BILLING CODE 4164-01-P